Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy.
Muscle Nerve
; 32(6): 775-81, 2005 Dec.
Article
em En
| MEDLINE
| ID: mdl-16116651
ABSTRACT
Several GTP-binding protein (G-protein)-coupled receptors that signal through Galphas (GTP-binding protein alpha stimulatory) and the cyclic adenosine monophosphate (cAMP) pathway increase skeletal muscle mass. In order to further evaluate the role of the cAMP pathway in the regulation of skeletal muscle mass, we utilized inhibitors of phosphodiesterase 4 (PDE 4), the major cAMP-modifying PDE found in skeletal muscle, to modulate skeletal muscle cAMP levels. We found that PDE 4 inhibitors reduced the loss of muscle mass and force resulting from denervation and casting in rats and mice. These studies indicate that PDE 4 inhibitors may have a role in the treatment of skeletal muscle-wasting diseases.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Inibidores de Fosfodiesterase
/
Atrofia Muscular
/
3',5'-AMP Cíclico Fosfodiesterases
/
Músculo Esquelético
Tipo de estudo:
Etiology_studies
Limite:
Animals
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article